Top

Published in:

Open Access 01-12-2020 | Computed Tomography | Study protocol

Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)

Authors: Sander C. Ebbers, Arthur J. A. T. Braat, Adriaan Moelker, Marcel P. M. Stokkel, Marnix G. E. H. Lam, Maarten W. Barentsz

Published in: Trials | Issue 1/2020

Abstract

Background

Lutetium-177-DOTA-octreotate (¹⁷⁷Lu-DOTATATE) significantly increases survival and response rates in patients with grade I and grade II neuroendocrine tumors (NETs). However, survival and response rates are significantly lower in patients with bulky liver metastases. Increasing the tumor-absorbed dose in liver metastases may improve response to ¹⁷⁷Lu-DOTATATE. The LUTIA (Lutetium Intra-Arterial) study aims to increase the tumor-absorbed dose in liver metastases by intra-arterial (IA) administration of ¹⁷⁷Lu-DOTATATE, compared to conventional intravenous (IV) administration.

Methods

A multicenter, within-patient randomized controlled trial (RCT) in 26 patients with progressive, liver-dominant, unresectable grade I or grade II NET will be conducted. Patients with bilobar bulky disease will be randomly allocated to receive IA treatment into either the left or the right hepatic artery. Using this approach, one liver lobe will be treated intra-arterially (first-pass effect), while the contralateral lobe will receive an intravenous treatment as a second-pass effect. The primary endpoint of this study is the difference in tumor-to-non-tumor ratio of ¹⁷⁷Lu-DOTATATE uptake between the two liver lobes on post-treatment SPECT/CT (IA versus IV). Secondary endpoints include absorbed dose in both liver lobes, tumor response, dose-response relationship, toxicity, uptake in extrahepatic lesions, and renal uptake.

Discussion

This multicenter, within-patient RCT will investigate whether IA administration of ¹⁷⁷Lu-DOTATATE results in a higher activity concentration in liver metastases compared to IV administration.

Trial registration

ClinicalTrials.gov, NCT03590119. Registered on 17 July 2018.

Available only for authorised users

Pavel M, O’Toole D, Costa F, et al. ENETS Consensus Guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172–85. https://doi.org/10.1159/000443167.CrossRefPubMed

Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25(3):458–511. https://doi.org/10.1210/er.2003-0014.CrossRefPubMed

Lepage C, Bouvier AM, Faivre J. Endocrine tumours: epidemiology of malignant digestive neuroendocrine tumours. Eur J Endocrinol. 2013;168(4):R77–83. https://doi.org/10.1530/EJE-12-0418.CrossRefPubMed

Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909–18. https://doi.org/10.1677/ERC-10-0152.CrossRefPubMed

Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of ¹⁷⁷ Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35. https://doi.org/10.1056/NEJMoa1607427.CrossRefPubMedPubMedCentral

Delpassand ES, Samarghandi A, Zamanian S, et al. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors. Pancreas. 2014;43(4):518–25. https://doi.org/10.1097/MPA.0000000000000113.CrossRefPubMed

Kam BLR, Teunissen JJM, Krenning EP, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(S1):103–12. https://doi.org/10.1007/s00259-011-2039-y.CrossRefPubMedCentral

Dash A, Pillai MRA, Knapp FF. Production of ¹⁷⁷Lu for targeted radionuclide therapy: available options. Nucl Med Mol Imaging. 2015;49(2):85–107. https://doi.org/10.1007/s13139-014-0315-z.CrossRefPubMedPubMedCentral

Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [¹⁷⁷Lu-DOT ⁰,Tyr ³]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617–24. https://doi.org/10.1158/1078-0432.CCR-16-2743.CrossRefPubMed

10.

Sabet A, Dautzenberg K, Haslerud T, et al. Specific efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging. 2015;42(8):1238–46. https://doi.org/10.1007/s00259-015-3041-6.CrossRefPubMed

11.

Ezziddin S, Khalaf F, Vanezi M, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41(5):925–33. https://doi.org/10.1007/s00259-013-2677-3.CrossRefPubMed

12.

Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-Octreotate. J Nucl Med. 2014;55(2):183–90. https://doi.org/10.2967/jnumed.113.125336.CrossRefPubMed

13.

Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [¹⁷⁷Lu-DOTA⁰,Tyr³ ]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–30. https://doi.org/10.1200/JCO.2007.15.2553.CrossRefPubMed

14.

Strosberg J, Hendifar A, Yao JC, et al. Impact of liver tumor burden on therapeutic effect of ¹⁷⁷Lu-dotatate treatment in NETTER-1 study. Ann Oncol. 2018;29(Suppl 8):1316P. https://doi.org/10.1093/annonc/mdy293.009.CrossRef

15.

Ebbers S, Barentsz M, Braat A, Lam M. Intra-arterial peptide receptor radionuclide therapy for neuroendocrine tumor liver metastases. Dig Dis Interv. 2019;03(1):081–90. https://doi.org/10.1055/s-0038-1676300.CrossRef

16.

Cornu C, Kassai B, Fisch R, et al. Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet J Rare Dis. 2013;8(1):48. https://doi.org/10.1186/1750-1172-8-48.CrossRefPubMedPubMedCentral

17.

Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200. https://doi.org/10.7326/0003-4819-158-3-201302050-00583.CrossRefPubMedPubMedCentral

18.

Klöppel G, Couvelard A, Perren A, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009;90(2):162–6. https://doi.org/10.1159/000182196.CrossRefPubMed

19.

Advanced Accelerator Applications. Summary of product characteristics. 2017. https://euhcp.lutathera.com/.

20.

Kupitz D, Wetz C, Wissel H, et al. Software-assisted dosimetry in peptide receptor radionuclide therapy with ¹⁷⁷Lutetium-DOTATATE for various imaging scenarios. PLoS One. 2017;12(11):e0187570. https://doi.org/10.1371/journal.pone.0187570.CrossRefPubMedPubMedCentral

21.

Li T, Ao ECI, Lambert B, Brans B, Vandenberghe S, Mok GSP. Quantitative imaging for targeted radionuclide therapy dosimetry - technical review. Theranostics. 2017;7(18):4551–65. https://doi.org/10.7150/thno.19782.CrossRefPubMedPubMedCentral

22.

Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Investig New Drugs. 1992;10(4):239–53. https://doi.org/10.1007/BF00944177.CrossRef

23.

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.CrossRefPubMed

24.

Lencioni R, Llovet J. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(01):052–60. https://doi.org/10.1055/s-0030-1247132.CrossRef

25.

National Cancer Institute. Common terminology criteria for adverse events version 4.03. 2009. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Published 2014. Accessed 5 June 2019.

26.

McStay MKG, Maudgil D, Williams M, et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90 Y-DOTA-Lanreotide as effective palliative therapy. Radiology. 2005;237(2):718–26. https://doi.org/10.1148/radiol.2372041203.CrossRefPubMed

27.

Limouris GS, Karfis I, Chatzioannou A, et al. Super-selective hepatic arterial infusions as established technique (“ARETAIEION” protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors. Q J Nucl Med Mol Imaging. 2012;56(6):551–8.PubMed

28.

Limouris GS, Poulantzas V, Trompoukis N, et al. Comparison of 111In-[DTPA0]octreotide versus non carrier added 177Lu- [DOTA0,Tyr3]-octreotate efficacy in patients with GEP-NET treated intra-arterially for liver metastases. Clin Nucl Med. 2016;41(3):194–200. https://doi.org/10.1097/RLU.0000000000001096.CrossRefPubMed

29.

Limouris GS, Chatziioannou A, Kontogeorgakos D, et al. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging. 2008;35(10):1827–37. https://doi.org/10.1007/s00259-008-0779-0.CrossRefPubMed

30.

Kratochwil C, López-Benítez R, Mier W, et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr Relat Cancer. 2011;18(5):595–602. https://doi.org/10.1530/ERC-11-0144.CrossRefPubMedPubMedCentral

31.

Kratochwil C, Giesel FL, Lopez-Benitez R, et al. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res. 2010;16(10):2899–905. https://doi.org/10.1158/1078-0432.CCR-10-0004.CrossRefPubMed

32.

Pool SE, Kam BLR, Koning GA, et al. [111 In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy. Cancer Biother Radiopharm. 2014;29(4):179–87. https://doi.org/10.1089/cbr.2013.1552.CrossRefPubMed

33.

Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72. https://doi.org/10.1016/S1470-2045(07)70410-2.CrossRefPubMed

34.

de Mestier L, Zappa M, Hentic O, Vilgrain V, Ruszniewski P. Liver transarterial embolizations in metastatic neuroendocrine tumors. Rev Endocr Metab Disord. 2017;18(4):459–71. https://doi.org/10.1007/s11154-017-9431-2.CrossRefPubMed

35.

Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer. 2015;121(8):1172–86. https://doi.org/10.1002/cncr.28760.CrossRefPubMed

36.

Jia Z, Wang W. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review. Eur J Radiol. 2018. https://doi.org/10.1016/j.ejrad.2018.01.012.CrossRefPubMed

37.

Braat AJAT, Kappadath SC, Ahmadzadehfar H, et al. Radioembolization with 90 Y resin microspheres of neuroendocrine liver metastases: international multicenter study on efficacy and toxicity. Cardiovasc Intervent Radiol. 2019;42(3):413–25. https://doi.org/10.1007/s00270-018-2148-0.CrossRefPubMed

38.

Devcic Z, Rosenberg J, Braat AJA, et al. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med. 2014;55(9):1404–10. https://doi.org/10.2967/jnumed.113.135855.CrossRefPubMed

39.

Do Minh D, Chapiro J, Gorodetski B, et al. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol. 2017;27(12):4995–5005. https://doi.org/10.1007/s00330-017-4856-2.CrossRefPubMedPubMedCentral

40.

Chen JX, Rose S, White SB, et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc Intervent Radiol. 2017;40(1):69–80. https://doi.org/10.1007/s00270-016-1478-z.CrossRefPubMed

41.

Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8–21. https://doi.org/10.1016/S1470-2045(13)70362-0.CrossRefPubMed

42.

Maccauro M, Follacchio GA, Spreafico C, Coppa J, Seregni E. Safety and efficacy of combined peptide receptor radionuclide therapy and liver selective internal radiation therapy in a patient with metastatic neuroendocrine tumor. Clin Nucl Med. 2019;44(4):e286–8. https://doi.org/10.1097/RLU.0000000000002480.CrossRefPubMed

43.

Filippi L, Ciorra A, Sardella B, Schillaci O, Bagni O. Sequential use of (90)Y microspheres radioembolization and (177)Lu-Dotatate in pluri-metastatic neuroendocrine tumors: a case report. Nucl Med Mol Imaging (2010). 2014;48(4):321–5. https://doi.org/10.1007/s13139-014-0292-2.CrossRef

44.

Ezziddin S, Meyer C, Kahancova S, et al. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med. 2012;53(11):1663–9. https://doi.org/10.2967/jnumed.112.107482.CrossRefPubMed

Title: Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)
Authors: Sander C. Ebbers
Arthur J. A. T. Braat
Adriaan Moelker
Marcel P. M. Stokkel
Marnix G. E. H. Lam
Maarten W. Barentsz
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Computed Tomography
Metastasis
Computed Tomography
Neuroendocrine Tumor
Published in: Trials / Issue 1/2020
Electronic ISSN: 1745-6215
DOI: https://doi.org/10.1186/s13063-019-3888-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)

Abstract

Background

Methods

Discussion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2020

Sinako, a study on HIV competent households in South Africa: a cluster-randomised controlled trial protocol

The effectiveness of a web-based decision aid for patients with hip osteoarthritis: study protocol for a randomized controlled trial

Study of Medical Ultrasound for Rhizarthrosis (SUR): study protocol for a randomized controlled single-center pilot-trial

Exploring the recruitment, ethical considerations, conduct and information dissemination of an audiology trial: a pretrial qualitative study (q-COACH)

Simultaneous reduction of flow and fraction of inspired oxygen (FiO2) versus reduction of flow first or FiO2 first in patients ready to be weaned from high-flow nasal cannula oxygen therapy: study protocol for a randomized controlled trial (SLOWH trial)

Adjunct low-dose ketamine infusion vs standard of care in mechanically ventilated critically ill patients at a Tertiary Saudi Hospital (ATTAINMENT Trial): study protocol for a randomized, prospective, pilot, feasibility trial